We are pleased to announce the publication of results for the latest clinical study using B-GOS. The human study, conducted by Nottingham Trent University’s School of Science and Technology, demonstrated a significant 40% reduction in the severity of exercise-induced asthma following consumption of B-GOS.
The study is published in the British Journal of Nutrition and entitled “A prebiotic galactooligosaccharide mixture reduces severity of hyperpnoeainduced bronchoconstriction and markers of airway inflammation”. It reports a substantial reduction in airway narrowing and inflammation in adults with exercise induced asthma following intake of B-GOS for three weeks.
Over five million people have asthma in the UK1, and 334 million worldwide2. Exercise induced asthma can affect up to 90% of asthma patients. The Global Asthma Network (GAN) Steering Group estimates from studies in The Global Asthma Report 2014 that the economic cost of asthma to society was $56 billion in the US in 2007 and €19.3 billion in Europe in 2011. Indirect costs of asthma, especially the negative impact on productivity, are at least as large as the direct costs.
“The finding that B-GOS can reduce exercise induced bronchoconstriction will be of great interest to clinicians and asthma sufferers alike. Although this is early stage work, it raises the prospect that our unique carbohydrate complex could be used as an adjunct to existing asthma therapy. This could potentially benefit millions of sufferers,” said Graham Waters, CEO, Clasado. “This new study adds to Clasado’s growing portfolio of clinical and pre-clinical research demonstrating efficacy across a wide variety of different health conditions from metabolic syndrome to anxiety.”
The clinical study is the latest in a 12 year on-going research programme of pre-clinical and clinical trials being undertaken by Clasado in collaboration with a range of internationally recognised research institutes. These studies have demonstrated efficacy in a diverse range of health areas including metabolic syndrome immune function, irritable bowel syndrome, stress management and pathogen protection. “Our study shows that B-GOS could be used as a potential additional therapy for exercise-induced asthma,” lead researcher Dr Neil Williams, a lecturer in exercise physiology and nutrition at Nottingham Trent University’s School of Science and Technology confirmed. “We are only just starting to understand the role the gut microbiome plays in health and disease – and it is becoming increasingly recognised that microbes living in the gut can have a substantial influence on immune function and allergies which is likely to be important in airway disease. B-GOS significantly increases the growth and activity of good gut bacteria. This in turn may reduce the inflammatory response of the airways in asthma patients to exercise. Importantly, the level of improvement in lung function that appears after administration of B-GOS is perceivable by the patient and therefore potentially clinically relevant.”
In the double blind crossover study 10 participants with exercise induced asthma and 8 control participants without asthma were randomised to receive B-GOS or placebo for 3 weeks separated by a 2 week washout.
Participants undertook a hyperventilation test in the laboratory, which causes reductions in lung function replicating the symptoms and severity associated with exercise induced asthma. The falls in lung function after the hyperventilation test were compared after three weeks of prebiotic B-GOS and placebo. Blood tests also studied circulating markers of airway inflammation.
Participants receiving B-GOS demonstrated a dramatic reduction in the severity of exercise-induced asthma. B-GOS was able to suppress resting blood markers of airway inflammation (CCL17, and CRP) and completely abolish the increase in cytokine TNF-α which usually occurs with airway constriction following exercise.